Cognitive-behavioural group treatment for a range of functional somatic syndromes: Lessons learned from the STreSS-1 trial

A placebo-controlled double blind trial

A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome : Results from N00C1 from the North Central Cancer Treatment Group

✍ Aminah Jatoi; Shaker R. Dakhil; Phuong L. Nguyen; Jeff A. Sloan; John W. Kugler; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB

## Abstract ## BACKGROUND. Tumor necrosis factor‐α (TNF‐α) is a putative mediator of the cancer anorexia/weight loss syndrome. The current study was designed to determine whether etanercept (a dimeric fusion protein consisting of the extracellular ligand‐binding portion of the human 75‐kilodalton